BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36485103)

  • 21. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase.
    Gupta V; Kennedy JA; Capo-Chichi JM; Kim S; Hu ZH; Alyea EP; Popat UR; Sobecks RM; Scott BL; Gerds AT; Salit RB; Deeg HJ; Nakamura R; Saber W
    Blood Adv; 2020 Nov; 4(21):5562-5573. PubMed ID: 33170935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Odenike O
    Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
    Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
    Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
    Saha C; Attwell L; Harrison CN; McLornan DP
    Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
    Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
    Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
    Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
    Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
    Chen D; Fuda F; Weinberg O
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
    Yogarajah M; Tefferi A
    Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Chauvet P; Nibourel O; Berthon C; Goursaud L; Carpentier B; Lionne-Huyghe P; Wemeau M; Quesnel B
    Leuk Res; 2022 Jul; 118():106871. PubMed ID: 35633618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
    Brune MM; Rau A; Overkamp M; Flaadt T; Bonzheim I; Schürch CM; Federmann B; Dirnhofer S; Fend F; Tzankov A
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
    Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
    Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.
    Chen J; Wang K; Xiao Z; Xu Z
    Ann Med; 2023 Dec; 55(1):348-360. PubMed ID: 36644935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
    Abruzzese E; Niscola P
    Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
    Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
    Tam CS; Nussenzveig RM; Popat U; Bueso-Ramos CE; Thomas DA; Cortes JA; Champlin RE; Ciurea SE; Manshouri T; Pierce SM; Kantarjian HM; Verstovsek S
    Blood; 2008 Sep; 112(5):1628-37. PubMed ID: 18566326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Cahu X; Chevallier P; Clavert A; Suarez F; Michallet M; Vincent L; Vigouroux S; Blaise D; Mariette C; Bilger K; Robin M; Yakoub-Agha I; Peffault de Latour R; Mohty M
    Bone Marrow Transplant; 2014 Jun; 49(6):756-60. PubMed ID: 24614840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.